Treeline Biosciences

About Treeline Biosciences

Treeline Biosciences aspires to create great medicines reliably and repeatedly. They focus on matching compelling disease targets with proven drug approaches by integrating in-house R&D with leading-edge computational tools. Their goal is to redefine the treatment of cancer and other serious diseases through a target-centric pipeline.

Products & Services

Medicines for Serious Diseases:Designing drug candidates such as inhibitors, protein degraders, and antibody drug conjugates targeting cancer, autoimmune, and neurological diseases using in-house R&D and computational tools.

Specialties

Cancer treatment Autoimmune disease treatment Neurological disease treatment In-house R&D Computational drug discovery Machine learning in drug design

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A extension T: - FT: Series A extension	A: 200000000 MR: - FA: $200 million FAN: 200000000	D: 2025-09-03 FD: 2025-09-03	12 investors

Series A extension Latest

2025-09-03

$200.0M

12 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Josh Bilenker

CEO and Co-Founder

J

Jeff Engelman

CSO and Co-Founder

Recent News